PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22421507-1	2013	Numerous experimental studies in recent years have suggested that erythropoietin (EPO) is an endogenous mediator of neuroprotection in various central nervous system disorders, including TBI.	Thioacetazone	187-190	erythropoietin	Homo sapiens	66-80	
22421507-1	2013	Numerous experimental studies in recent years have suggested that erythropoietin (EPO) is an endogenous mediator of neuroprotection in various central nervous system disorders, including TBI.	Thioacetazone	187-190	erythropoietin	Homo sapiens	82-85	
22421507-2	2013	Many characteristics of EPO neuroprotection that have been defined in TBI experimental models suggest that it is an attractive candidate for a new treatment of TBI.	Thioacetazone	70-73	erythropoietin	Homo sapiens	24-27	
22421507-2	2013	Many characteristics of EPO neuroprotection that have been defined in TBI experimental models suggest that it is an attractive candidate for a new treatment of TBI.	Thioacetazone	160-163	erythropoietin	Homo sapiens	24-27	
22421507-3	2013	EPO targets multiple mechanisms known to cause secondary injury after TBI, including anti-excitotoxic, antioxidant, anti-edematous, and anti-inflammatory mechanisms.	Thioacetazone	70-73	erythropoietin	Homo sapiens	0-3	
18789503-7	2009	With the recent interest in clinical trials of EPO in human stroke, it is both timely and prudent to consider the use of this pharmaceutical avenue in TBI in man.	Thioacetazone	151-154	erythropoietin	Homo sapiens	47-50	
17935704-3	2007	This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI.	Thioacetazone	147-150	erythropoietin	Homo sapiens	78-81	
17935704-12	2007	EPO, administered in its recombinant form, affords significant neuroprotection in experimental TBI model and may hold promise for future clinical applications.	Thioacetazone	95-98	erythropoietin	Homo sapiens	0-3	
30864534-0	2019	Longitudinal Changes in Disability Rating Scale Scores: A Secondary Analysis Among Patients With Severe TBI Enrolled in the Epo Clinical Trial.	Thioacetazone	104-107	erythropoietin	Homo sapiens	124-127	
30864534-7	2019	TBI severity group was found to significantly interact with Epo randomization group on mean DRS recovery curves.	Thioacetazone	0-3	erythropoietin	Homo sapiens	60-63